On February 15th, an article on the front page of Securities Daily stated that as we enter 2025, listed pharmaceutical companies such as Oppenheim and Bide Pharmaceuticals have successively released merger and acquisition plans, signaling a continuous increase in market activity. Looking ahead, the four major factors will jointly support the continued rise of mergers and acquisitions in China’s pharmaceutical industry. Firstly, the trend of large-scale and intensive development in the pharmaceutical industry is further highlighted. Secondly, pharmaceutical companies seek sustainable development, and mergers and acquisitions are important means to achieve this goal. Once again, the optimization of policy environment has provided strong support for mergers and acquisitions in the pharmaceutical industry. Finally, the current valuation of the pharmaceutical industry’s secondary market has dropped to historically low levels, which is conducive to industry mergers and acquisitions. In general, a lower valuation means that the target company’s price is relatively reasonable and the cost of mergers and acquisitions is relatively low, which enhances the attractiveness and feasibility of mergers and acquisitions. With the joint efforts of multiple parties, the activity of mergers and acquisitions in the pharmaceutical industry will continue to increase, which is not only conducive to enhancing the overall competitiveness and sustainable development ability of the pharmaceutical industry, but also helps to promote the high-quality development of the capital market.
Scan code to share